Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cybis 10:25
- Development stage
- Phase 2
- Lead developer
- Cymra Life Sciences
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Oromucosal
01
Overview
Cybis 10:25 is an oromucosal oil formulation containing a fixed ratio of tetrahydrocannabinol (THC) and cannabidiol (CBD), specifically 10 mg THC and 25 mg CBD per mL, dissolved in medium-chain triglycerides. The product is designed so that the CBD component counteracts the psychoactive effects of THC while also contributing to analgesic activity. Cybis 10:25 has been studied for use in patients with moderate to severe chronic back or neck pain unresponsive to over-the-counter non-opioid analgesics. In clinical studies, it demonstrated dose-dependent reductions in pain as well as improvements in depressive symptoms and stress. The mechanism of action involves modulation of cannabinoid receptors by both THC and CBD[1][3].
- Brand names
- cybis 10:25cymra cybis 10:25
- Other names
- THC:CBD 10:25 preparationCybis 10:25 oromucosal oil
02
Targets
CNR2 (Cannabinoid receptor type 2)
Beyond the preview
Go deeper on Cybis 10:25.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cybis 10:25.